Cargando…

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

INTRODUCTION: Triple-negative breast cancer (TNBC) patients who do not obtain pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) present higher rate of relapse and worse overall survival. Risk factors for relapse in this subset of patients are poorly characterized. This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toss, Angela, Venturelli, Marta, Civallero, Monica, Piombino, Claudia, Domati, Federica, Ficarra, Guido, Combi, Francesca, Cabitza, Eleonora, Caggia, Federica, Barbieri, Elena, Barbolini, Monica, Moscetti, Luca, Omarini, Claudia, Piacentini, Federico, Tazzioli, Giovanni, Dominici, Massimo, Cortesi, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753128/ https://www.ncbi.nlm.nih.gov/pubmed/36531080 http://dx.doi.org/10.3389/fonc.2022.1016295

Ejemplares similares

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
por: Isca, Chrystel, et al.
Publicado: (2021)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
por: Canino, Fabio, et al.
Publicado: (2022)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022)

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
por: Cerma, Krisida, et al.
Publicado: (2023)

BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy
por: Toss, Angela, et al.
Publicado: (2020)

Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
por: Toss, A., et al.
Publicado: (2021)

Management of PALB2‐associated breast cancer: A literature review and case report
por: Toss, Angela, et al.
Publicado: (2023)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Personalized Systemic Therapies in Hereditary Cancer Syndromes
por: Mastrodomenico, Luciana, et al.
Publicado: (2023)

Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2019)

The Role of Exosomes in Breast Cancer Diagnosis
por: Piombino, Claudia, et al.
Publicado: (2021)

The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study
por: Toss, Angela, et al.
Publicado: (2021)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
por: Omarini, Claudia, et al.
Publicado: (2018)

BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees
por: Cortesi, Laura, et al.
Publicado: (2021)

Male mammary myofibroblastoma: Two case reports and brief review of literature
por: Venturelli, Marta, et al.
Publicado: (2020)

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications
por: Toss, Angela, et al.
Publicado: (2018)

Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study
por: Cortesi, Laura, et al.
Publicado: (2020)

Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe
por: Moscetti, L., et al.
Publicado: (2021)

Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
por: Venturelli, Marta, et al.
Publicado: (2018)

Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?
por: Cortesi, Laura, et al.
Publicado: (2021)

COVID-related disruption in mammographic screening: a year later
por: Toss, A., et al.
Publicado: (2022)

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
por: Cortesi, L., et al.
Publicado: (2023)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA
por: Piombino, Claudia, et al.
Publicado: (2020)

Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
por: Toss, Angela, et al.
Publicado: (2017)

GD2 expression in breast cancer
por: Orsi, Giulia, et al.
Publicado: (2017)

Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles
por: Cortesi, Laura, et al.
Publicado: (2021)

Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?
por: Reggiani Bonetti, Luca, et al.
Publicado: (2017)

Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors
por: Piombino, Claudia, et al.
Publicado: (2022)

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
por: Omarini, Claudia, et al.
Publicado: (2020)

Application of OSNA Nomogram in Patients With Macrometastatic Sentinel Lymph Node: A Retrospective Assessment of Accuracy
por: Combi, Francesca, et al.
Publicado: (2021)

Breast ultrasound in high-risk women
por: Cortesi, Laura, et al.
Publicado: (2019)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
por: Cortesi, Laura, et al.
Publicado: (2022)

Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study
por: Isca, Chrystel, et al.
Publicado: (2022)

Molecular Features and Methylation Status in Early Onset (≤40 Years) Colorectal Cancer: A Population Based, Case-Control Study
por: Magnani, Giulia, et al.
Publicado: (2015)

Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review
por: Maur, Michela, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gj93ah7bnks9q9kojhfmbqf835